Drivers of vaginal drug delivery system acceptability from internet-based conjoint analysis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Primrose, Rachel J ^a,b   Zaveri, Toral ^a,b   Bakke, Alyssa J ^a,b   Ziegler, Gregory R ^b   Moskowitz, Howard R ^c   Hayes, John E ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Mind Genomics Assoc Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROBICIDE; UNCLASSIFIED DRUG; VAGINAL MICROBICIDE;

ADULT; AGE DISTRIBUTION; ARTICLE; AWARENESS; CLINICAL EFFECTIVENESS; CONJOINT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDEAMAP; INFECTION PREVENTION; INFORMATION PROCESSING; INTERNET; KNOWLEDGE; MEDICAL INFORMATION; OUTCOME ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SOCIAL BEHAVIOR; STATISTICAL ANALYSIS; UNITED STATES; WOMEN'S HEALTH; YOUNG ADULT; ADOLESCENT; DRUG DELIVERY SYSTEM; INTRAVAGINAL DRUG ADMINISTRATION; MALE; PATIENT ATTITUDE; QUESTIONNAIRE; THREE DIMENSIONAL IMAGING;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; INTERNET; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84962468915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150896     Document Type: Article

References (52)

1. Global report: UNAIDS report on the global AIDS epidemic: 2012. UNAIDS, 2012 9291739960.
2. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. World Health Organization, 2012.
3. Prevention CoDCa. Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States 2013; 2014 (November 18, 2014). Available: http://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf.
4. HIV Among Women. Centers of Disease Control and Prevention, 2014 Contract No.: November 18, 2014.
5. Pennsylvania - 2013 State Health Profile. Centers of Disease Control and Prevention 2013 Contract No.: November 18, 2014.
6. Fact Sheet About Microbicides. Microbicide Trials Network, 2014 Contract No.: November 18, 2014.
7. Akil A, Parniak MA, Dezzuitti CS, Moncla BJ, Cost MR, Li M, et al. Development and Characterization of a Vaginal Film Containing Dapivirine, a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug delivery and translational Research. 2011; 1(1): 209-22. doi: 10.1007/s13346-011-0022-6 PMID: 22708075; PubMed Central PMCID: PMC3375737.
8. Cole AM, Patton DL, Rohan LC, Cole AL, Cosgrove-Sweeney Y, Rogers NA, et al. The Formulated Microbicide RC-101 Was Safe and Antivirally Active Following Intravaginal Application in Pigtailed Macaques. PLoS One. 2010; 5(5):e15111. doi: 10.1371/journal.pone.0015111 PMID: 21124745
9. Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Research. 2013; 100, Supplement(0):S3-S8. doi: 10.1016/j.antiviral.2013.09.025
10. Fetherston SM, Boyd P, McCoy CF, McBride MC, Edwards K-L, Ampofo S, et al. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. European Journal of Pharmaceutical Sciences. 2013; 48(48):406-15. doi: 10.1016/j.ejps.2012.12.002 PMID: 23266465
11. Hoffman S, Morrow K, Mantell J, Rosen R, Carballo-Diéguez A, Gai F. Covert Use, Vaginal Lubrication, and Sexual Pleasure: A Qualitative Study of Urban U.S. Women in a Vaginal Microbicide Clinical Trial. Arch Sex Behav. 2010; 39(39):748-60. doi: 10.1007/s10508-009-9509-3 PMID: 19636696
12. Li B, Zaveri T, Ziegler GR, Hayes JE. Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral Research. 2013; 97(97):280-4. doi: 10.1016/j.antiviral.2012.12.024 PMID: 23276592
13. Li B, Zaveri T, Ziegler GR, Hayes JE. User Preferences in a Carrageenan-Based Vaginal Drug Delivery System. PLoS One. 2013; 8(8). doi: 10.1371/journal.pone.0054975
14. Hammett TM, Mason TH, Joanis CL, Foster SE, Harmon P, Robles RR, et al. Acceptability of Formulations and Application Methods for Vaginal Microbicides Among Drug-Involved Women: Results of Product Trials in Three Cities. Sexually Transmitted Diseases. 2000; 27(27):119-26. PMID: 10676980
15. Robertson AM, Syvertsen JL, Martinez G, Rangel MG, Palinkas LA, Stockman JK, et al. Acceptability of vaginal microbicides among female sex workers and their intimate male partners in two Mexico - US border cities: A mixed methods analysis. Global Public Health. 2013; 8(8):619-33. doi: 10.1080/17441692.2012.762412 PMID: 23398385
16. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010; 363(363):2587-99. doi: 10.1056/NEJMoa1011205 PMID: 21091279
17. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovirgel, an antiretroviral microbicide, for the prevention of HIV infection in women. science. 2010; 329(329):1168-74. doi: 10.1126/science.1193748 PMID: 20643915
18. Karim SSA, Karim QA. Antiretroviral prophylaxis: A defining moment for HIV prevention. Lancet. 2011; 378(378):e23. doi: 10.1016/S0140-6736(11)61136-7 PMID: 21771566
19. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine. 2015; 372(372):509-18. doi: 10.1056/NEJMoa1402269 PMID: 25651245.
20. Rees H, Delaney-More S, Baron D, Lombard C, Gray G, Myer L, et al. editor FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. Conference on Retroviruses and Opportunistic Infections (CROI); 2015; Seattle, WA.
21. van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women's Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS One. 2014; 9(9):e89118. doi: 10.1371/journal.pone.0089118 PMID: 24586534
22. Rosen M, vanden Berg JJ, Vargas S, Senocak N, Shaw JG, Buckheit RW, et al. Meaning-making matters in product design: Users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception. 2015. Epub 11th August 2015.
23. Green PE, Krieger AM, Wind Y. Thirty years of conjoint analysis: Reflections and prospects. Interfaces. 2001; 31(3-supplement):S56-S73.
24. Green PE, Srinivasan V. Conjoint analysis in marketing: New developments with implications for research and practice. The Journal of Marketing. 1990:3-19.
25. Beusterien KM, Dziekan K, Flood E, Harding G, Jordan JC. Understanding Patient Preferences for HIV Medications Using Adaptive Conjoint Analysis: Feasibility Assessment. Value in Health. 2005; 8(8): 453-61. doi: 10.1111/j.1524-4733.2005.00036.x PMID: 16091022
26. Kinsler JJ, Cunningham WE, Nureña CR, Nadjathaiem C, Grinsztejn B, Casapia M, et al. Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities. AIDS and Behavior. 2012; 16(16):1436-47. doi: 10.1007/s10461-011-0045-51027176583; PMID: 21959986.
27. Lee SJ, Newman PA, Comulada WS, Cunningham WE, Duan N. Use of conjoint analysis to assess HIV vaccine acceptability: Feasibility of an innovation in the assessment of consumer health-care preferences. International journal of STD & AIDS. 2012; 23(23):235-41. doi: 10.1258/ijsa.2011.011189
28. Weaver JMPH, Newman PAP, Williams CCP, Massaquoi NMSW, Brown MMSW. "Sisters, Mothers, Daughters and Aunties": HIV Vaccine Acceptability Among African, Caribbean and Other Black Women in Toronto. Canadian Journal of Public Health. 2013; 104(104):e413-7.1459652402; PMID: 24183184.
29. Holt BY, Morwitz VG, Ngo L, Harrison PF, Whaley KJ, Pettifor A, et al. Microbicide preference among young women in California. Journal of Women's Health. 2006; 15(15):281-94. PMID: 16620187
30. Giguere R, Carballo-Dieguez A, Ventuneac A, Mabragana M, Dolezal C, Chen BA, et al. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult Health Sex. 2012; 14(14):151-66. doi: 10.1080/13691058.2011.630099 ISI:000301710100003. PMID: 22084840
31. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. Journal of Women's Health. 2003; 12(12):655-66. doi: 10.1089/154099903322404302 ISI:000188439100005. PMID: 14583106
32. Nel AM, Mitchnick LB, Risha P, Muungo LT, Norick PM. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women. Journal of Women's Health (Larchmt). 2011; 20(20):1207-14. Epub 2011/07/22. doi: 10.1089/jwh.2010.2476 PMID: 21774672.
33. Zaveri T, Primrose RJ, Surapaneni L, Ziegler GR, Hayes JE. Firmness Perception Influences Women's Preferences for Vaginal Suppositories. Pharmaceutics. 2014; 6(6):512-29. doi: 10.3390/pharmaceutics6030512 PMID: 25211123
34. Zaveri T, Hayes JE, Ziegler GR. Release of tenofovir from carrageenan-based vaginal suppositories. Pharmaceutics. 2014; 6(6):366-77. doi: 10.3390/pharmaceutics6030366 PMID: 24999606
35. Mahan ED, Zaveri T, Ziegler GR, Hayes JE. Relationships between perceptual attributes and rheology in over-the-counter vaginal products: A potential tool for microbicide development. PLoS One. 2014; 9(9):e105614. Epub 2014/09/05. doi: 10.1371/journal.pone.0105614 PMID: 25188244; PubMed Central PMCID: PMC4154878.
36. Mahan ED, Morrow KM, Hayes JE. Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: Implications for microbicide development. Contraception. 2011; 84(84):184-93. Epub 2011/07/16. S0010-7824(10)00658-X[pii] doi: 10.1016/j.contraception.2010.11.012 PMID: 21757061.
37. Zaveri T, Powell KA, Li B, Ziegler GR, Hayes JE, editors. Improving acceptability of vaginal drug delivery systems by using sensory methods. The Society of Sensory Professionals 3rd Technical and Professional Conference; 2012 Oct 10-12; Jersey City, New Jersey.
38. Jansen S, Boumeester H, Coolen H, Goetgeluk R, Molin E. The impact of including images in a conjoint measurement task: Evidence from two small-scale studies. J Hous and the Built Environ. 2009; 24(24): 271-97. doi: 10.1007/s10901-009-9149-x
39. MJI-DesignLab. IdeaMap(R) White Plains, NY. 2014 [20 August 2014.].
40. Foley M, Beckley J, Ashman H, Moskowitz HR. The mind-set of teens towards food communications revealed by conjoint measurement and multi-food databases. Appetite. 2009; 52(52):554-60. doi: 10.1016/j.appet.2009.01.006 PMID: 19501750
41. Moskowitz HR, German JB, Saguy IS. Unveiling health attitudes and creating good-for-you foods: The genomics metaphor, consumer innovative web-based technologies. Critical reviews in food science and nutrition. 2005; 45(45):165-91. PMID: 16048147
42. Saulo AA, Moskowitz HR. Uncovering the mind-sets of consumers towards food safety messages. Food quality and preference. 2011; 22(22):422-32.
43. Levin LA, Langer KM, Clark DG, Colquhoun TA, Callaway JL, Moskowitz HR. Using Mind Genomics to Identify Essential Elementsofa Flower Product. Hort Science. 2012; 47(47):1658-65.
44. Colquhoun TA, Levin LA, Moskowitz HR, Whitaker VM, Clark DG, Folta KM. Framing the perfect strawberry: An exercise in consumer-assisted selection of fruit crops. Journal of Berry Research. 2012; 2(2): 45-61.
45. Moskowitz HR. 'Mind genomics': The experimental, inductive science of the ordinary, and its application to aspects of food and feeding. Physiol Behav. 2012; 107(107):606-13. PMID: 22542473.
46. Tanner AE, Katzenstein JM, Zimet GD, Cox DS, Cox AD, Fortenberry JD. Vaginal Microbicide Preferences Among Midwestern Urban Adolescent Women. The Journal of adolescent health: Official publication of the Society for Adolescent Medicine. 2008; 43(43):349-56. doi: 10.1016/j.jadohealth.2008.02. 017
47. Tanner AE, Zimet G, Fortenberry JD, Reece M, Graham C, Murray M. Young Women's Use of a Vaginal Microbicide Surrogate: The Role of Individual and Contextual Factors in Acceptability and Sexual Pleasure. The Journal of Sex Research. 2009; 46(46):15-23. doi: 10.1080/00224490802398407 PMID: 19012060
48. Terris-Prestholt F, Hanson K, MacPhail C, Vickerman P, Rees H, Watts C. How Much Demand for New HIV Prevention Technologies Can We Really Expect? Results from a Discrete Choice Experiment in South Africa. PLoS One. 2013; 8(8):e83193. doi: 10.1371/journal.pone.0083193 PMID: 24386160
49. van den Berg JJ, Rosen RK, Bregman DE, Thompson LA, Jensen KM, Kiser PF, et al. "Set it and forget it": Women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav. 2014; 18(18): 862-70. Epub 2013/11/20. doi: 10.1007/s10461-013-0652-4 PMID: 24248674; PubMed Central PMCID: PMC4018755.
50. National Survey of Sexual Health and Behavior. Center for Sexual Health Promotion, 2010 Contract No.: November 18, 2014.
51. Reiff M, Wade C, Chao MT, Kronenberg F, Cushman LF. Health Practices and Vaginal Microbicide Acceptability among Urban Black Women. Journal of Women's Health. 2008; 17(17):1345-51. doi: 10.1089/jwh.2008.0886 PMID: 18788991
52. Morrow KM, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt). 2003; 12(12):655-66. Epub 2003/10/30. doi: 10.1089/154099903322404302 PMID: 14583106.